AU Patent

AU2020341464A1 — Methods of treating epilepsy using the same

Assigned to Trevena Inc · Expires 2022-04-21 · 4y expired

What this patent protects

The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of S1P1 receptor and methods of using the same for the treatment of seizures, epilepsy related conditions,…

USPTO Abstract

The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of S1P1 receptor and methods of using the same for the treatment of seizures, epilepsy related conditions, epilepsy-related syndrome, and the like as described herein.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020341464A1
Jurisdiction
AU
Classification
—
Expires
2022-04-21
Drug substance claim
No
Drug product claim
No
Assignee
Trevena Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.